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Multiple observational studies have reported that post-
menopausal women who use estrogen have a lower rate of
coronary heart disease (CHD) events than women who do
not use estrogen (1). Meta-analyses of these epidemiologic
findings suggest a 35% to 50% reduction in risk of coronary
disease among women using estrogen compared to nonusers
(2,3). These findings are supported by plausible biologic
mechanisms including a beneficial effect of estrogen therapy
on low-density lipoprotein and high-density lipoprotein
cholesterol (4), improved endothelial function (5) and less
progression of atherosclerosis in animals (6). Thus, it was
very surprising when the results of the first large trial of the
effect of postmenopausal hormone therapy on risk for
coronary events showed no benefit of treatment.
The Heart and Estrogen/progestin Replacement Study
(HERS) was a randomized, blinded, clinical trial among
2,763 postmenopausal women with documented coronary
disease and a uterus; they were randomly assigned to receive
daily conjugated estrogen plus medroxyprogesterone acetate
or placebo. After an average of 4.1 years of follow-up, there
was no difference between the groups in the primary
composite outcome of nonfatal myocardial infarction (MI)
and coronary death or any of several secondary cardiovas-
cular outcomes (7). Even more surprisingly, HERS inves-
tigators found that women assigned to estrogen plus pro-
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gestin had a 50% increased risk of coronary events in the
first year of the trial. Within the first year, the risk was
highest in the first four months (relative hazard 2.3; 95%
confidence interval 0.9–5.6). This increased risk returned to
baseline over the subsequent two years, and risk appeared to
be lower in the hormone-treated group than in the placebo
group beginning in the third year of the trial. The early
increase in CHD risk observed in the HERS trial may have
occurred by chance or may be due to some adverse effect of
hormone therapy. To decide between these alternative
explanations, repetition of the HERS findings would be
helpful.
This issue of the Journal contains a report from the
Coumadin Aspirin Reinfarction Study (CARS), a random-
ized, blinded trial to test the effect of low-dose aspirin plus
low-dose warfarin compared to standard aspirin therapy for
the prevention of cardiovascular events in persons with a
recent MI (8). The CARS trial enrolled 8,803 participants
3 to 21 days after documented MI. The trial was stopped
after a median of 14 months of the planned two years of
follow-up because therapy with low-dose aspirin plus war-
farin was no more effective than standard aspirin mono-
therapy. In this issue of the Journal, Alexander et al. (9) used
data from the 1,857 postmenopausal women enrolled in
CARS in an observational cohort design to evaluate the
effect of initiation of hormone therapy on risk for coronary
events. Women who began hormone therapy after their MI
had a higher subsequent incidence of unstable angina than
women who had never used hormones (39% vs. 20%; p 5
0.001). Interestingly, however, new hormone users suffered
death or recurrent MI at a lower rate than never-users (4%
vs. 15%; p # 0.05). Follow-up was relatively short (median
14 months; maximum 33 months), but there was no
evidence that the higher rate of unstable angina observed
among new users compared to never-users decreased over
time.
These results differ in important ways from the results of
the HERS trial. In HERS, it was risk for recurrent MI or
coronary death that increased 50% in the first year of
treatment, and there was no clear evidence for any early or
overall effect on angina. In CARS, risk levels for recurrent
MI and death were lower among new users of hormone
therapy, and the rates of angina were doubled. These
differences in results presumably reflect the crucial difference
in design between CARS and HERS: HERS was a ran-
domized trial of the effect of hormone therapy and CARS
was not. The report in this issue of the Journal on the effect
of hormone therapy is an observational analysis that used
the CARS data in a prospective cohort design. Many
important baseline differences existed between new hor-
mone users and never-users in CARS. Statistical methods
were used to adjust for these measured differences, but there
is no way to adjust for unmeasured differences that can have
a major effect on the outcome (10,11).
Although data from the CARS analysis provide little
support for the HERS findings of early increased risk of MI
and death associated with hormone therapy, preliminary
data from another very large randomized trial are consistent.
The Women’s Health Initiative (WHI) randomized trial
includes approximately 27,000 women without coronary
disease who were randomized to receive estrogen plus a
progestin or placebo if they had a uterus, and estrogen or
placebo if not. The trial is now in approximately the third
year of a planned nine-year treatment period. Recently,
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investigators in the WHI issued a press release and wrote
letters to participants stating that they had observed an
increased risk of cardiovascular events among the hormone-
treated women in the first two years of the trial (12).
Although no quantitative risk estimates were given, these
results would not have been released in this fashion had they
not been substantial. Hormone therapy appears to be having
the same early adverse effect on coronary risk among these
healthy women as among women in HERS with docu-
mented coronary disease. Final results of the WHI are not
scheduled to be available for approximately four years.
Although the participants were men and the dose of
estrogen was high, the Coronary Drug Project also found
that estrogen therapy after MI produced a pattern of early
increase balanced by later decrease in new CHD events that
closely resembled the findings of HERS (13).
If postmenopausal hormone therapy causes an increased
risk of cardiovascular events early after starting therapy,
what is the etiology? Both HERS and CARS investigators
suggest that estrogen may cause thrombosis, arrhythmia or
ischemia. The increased risk might decline over time if only
a subset of users are susceptible to the adverse effect, or if
users develop some form of tolerance over time.
In an effort to identify women at risk of the adverse effect,
the HERS investigators examined multiple subgroups and
found that women with baseline lipoprotein(a) [Lp(a)]
below the median had a marked increase in risk of CHD
events in the first year of treatment with hormone therapy
(relative risk 2.1 compared with placebo; p # 0.05) and no
benefit thereafter (14). In contrast, HERS participants with
baseline Lp(a) above the median had less early harm and
more overall benefit (p 5 0.04). However, these findings are
post hoc and might have occured by chance as nearly 100
possible subgroups were evaluated.
Because hormone therapy increases risk for venous
thrombosis substantially (15), many investigators have as-
sumed that an early adverse effect of hormone therapy is
likely to be thrombotic. The effects of estrogen on coagu-
lation factors are mixed, but reported procoagulant effects
include increases in factors VII and X and protein C, and
decreases in antithrombin III (16). Estrogen also increases
levels of C-reactive protein (17,18), which is associated with
inflammation, coronary plaque instability and possibly
thrombosis (19). Psaty et al. (20) have reported observa-
tional evidence that hormone treatment is more likely to
cause MI in women who have the prothrombin 20210 G-A
variant and hypertension. These theories are plausible, but
currently there is no firm evidence to support them. The
HERS investigators are undertaking nested case-control
studies to evaluate subgroups of women defined by several
serum markers of coagulation and inflammation, but results
are not currently available.
Although uncertainties still exist about the early increase
in cardiovascular risk associated with postmenopausal hor-
mone therapy, the overall message from the available clinical
trials is clear. The HERS trial found no benefit of four years
of treatment with postmenopausal hormone therapy in
women with prior CHD (7). The Estrogen Replacement in
Atherosclerosis (ERA) trial found that neither estrogen
alone nor estrogen plus progestin was different from placebo
in the effects on progression of coronary disease measured
angiographically (18). A recent meta-analysis of small ran-
domized trials of short-term hormone treatment also found
no benefit (21). No randomized trial of hormone treatment
has found reduced risk of cardiovascular events among
postmenopausal women.
Randomized trials have established that hormone treat-
ment causes a threefold increased risk of venous thrombem-
bolism (15), and observational studies suggest that it may
increase the risk of breast cancer after many years of
treatment (22). In light of these adverse effects, and of the
many proven approaches to preventing CHD in high-risk
women (23,24), it seems clear that postmenopausal hor-
mone therapy should not be used for the purpose of
preventing coronary disease unless future data from well-
designed randomized trials document such benefit.
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